Drug Trial Radar · NCT05934331
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
632
Planned (sponsor's estimate)
Start
Jul 27, 2023
Primary completion
Aug 6, 2031
Study completion Aug 6, 2031
Sponsor
- Lead sponsor
- LaNova Medicines Zhejiang Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.
Conditions
- Malignant Neoplasms of Digestive Organs
Interventions
LM-302Drug
Q2W/Q3W,Administered intravenously
ToripalimabDrug
Q2W/Q3W,Administered intravenously
CapecitabineDrug
BID,Oral Administration
Tegafur, Gimeracil and Oteracil Potassium CapsulesDrug
BID,Oral Administration
NivolumabDrug
Q4W,Administered intravenously
ApatinibDrug
QD,Oral Administration
GemcitabineDrug
Q4W,Administered intravenously
TislelizumabDrug
Q2W Administered intravenously
AnlotinibDrug
QD,Oral Administration
BenmelstobartDrug
Q4W Administered intravenously
LM-302Drug
Q2W Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: 112 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.